Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Bernstein Upgrades Eni to Outperform

Bernstein Upgrades Eni to Outperform

Bernstein analyst Oswald Clint upgrades Eni (NYSE:E) from Market Perform to Outperform.

byBenzinga Newsdesk

January 3, 2023

1 minute read

Bernstein analyst Oswald Clint upgrades Eni (NYSE:E) from Market Perform to Outperform.

Analyst Ratings

4 Analysts Assess Arrowhead Pharma: What You Need To Know

By Benzinga Insights

January 2, 4:00 PM

Arrowhead Pharma (NASDAQ:ARWR) has been analyzed by 4 analysts in the last three months, revealing a diverse range…

ARWR

News

AMD Says Expect Not To Be Supply Constrained In 2023 Based On What We Currently See

By Benzinga Newsdesk

November 1, 5:33 PM

- Reuters

AMD

What’s Going On With Canopy Growth Stock Today?

By Erica Kollmann

September 7, 11:37 AM

Canopy Growth Corporation (NASDAQ: CGC) shares are trading lower on Thursday.

CGC

Eledon Secures FDA Clearance For Kidney Transplant Rejection Study

By Ragothaman Srinivasan

August 1, 7:34 AM

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ: ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant.

ELDN

Bernstein Upgrades Eni to Outperform

Related Posts

4 Analysts Assess Arrowhead Pharma: What You Need To Know

AMD Says Expect Not To Be Supply Constrained In 2023 Based On What We Currently See

What’s Going On With Canopy Growth Stock Today?

Eledon Secures FDA Clearance For Kidney Transplant Rejection Study